Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Clinical trial NCT04675333 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04675333
- Sponsor
- ALX Oncology Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-10
- Primary completion
- 2025-03-03
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.